Compare POOL & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POOL | KRYS |
|---|---|---|
| Founded | 1993 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5B | 7.8B |
| IPO Year | 1997 | 2017 |
| Metric | POOL | KRYS |
|---|---|---|
| Price | $205.38 | $251.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 10 |
| Target Price | $292.29 | ★ $297.60 |
| AVG Volume (30 Days) | ★ 691.4K | 195.7K |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.50% | N/A |
| EPS Growth | N/A | ★ 128.00 |
| EPS | ★ 10.85 | 6.84 |
| Revenue | ★ $5,289,396,000.00 | $389,130,000.00 |
| Revenue This Year | $4.51 | $40.88 |
| Revenue Next Year | $3.98 | $35.16 |
| P/E Ratio | ★ $18.49 | $36.80 |
| Revenue Growth | N/A | ★ 33.94 |
| 52 Week Low | $197.68 | $123.03 |
| 52 Week High | $345.00 | $298.30 |
| Indicator | POOL | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 36.28 | 43.56 |
| Support Level | N/A | $248.73 |
| Resistance Level | $227.80 | $293.60 |
| Average True Range (ATR) | 5.69 | 9.06 |
| MACD | 0.38 | -0.42 |
| Stochastic Oscillator | 28.67 | 30.85 |
Pool Corp distributes swimming pool supplies and related products. Its products include non-discretionary pool-maintenance products, like chemicals and replacement parts, as well as pool equipment, like packaged pools (kits to build swimming pools), cleaners, filters, heaters, pumps, and lights. Customers include pool builders and remodelers, independent retail stores, and pool repair and service companies.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.